Skip to main content
Equibles
IMCR logo

IMCR · Immunocore Holdings plc

Track IMCR — free

Use IMCR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$36.32 -0.30 (-0.82%) At close · Aug 31
Rebalance outlook locked
Market Cap
$1.89B
Shares
51.50M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.62 Open$36.64 Day$36.05–36.78 52W close$27.79–40.22 Avg vol 30d421K Short int7.9M · 15.3% float · 18.8d Short vol36% Last earningsAug 6, 2026 DataFeb 2021–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Feb 4, 2027 Est · unconfirmed · in 22 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

Q4 FY25 earnings call · Feb 25, 2026
Q4 FY25

TL;DR. Immunocore reported full-year 2025 KIMTRAK net revenues of $400 million, up 29% year-over-year, with the product now approved in 39 countries and launched in 30, alongside three ongoing Phase 3 oncology trials and pipeline expansion into ovarian, lung, autoimmune, HIV, and hepatitis B.

Bullish
  • + Full-year 2025 KIMTRAK net revenue of $400 million, up over 29% year-over-year, marking the fifteenth quarter of growth.
  • + KIMTRAK approved in 39 countries and launched in 30 markets, with 70% of prescriptions and half of patient starts coming from the community, and 150 new accounts activated in 2025.
  • + Real-world median overall survival of 28 months from 150 patients, mean duration of therapy of 14 months, and one in four patients alive at three years.
  • + Cash, cash equivalents and marketable securities of approximately $864 million as of December 31, 2025.
  • + Three ongoing Phase 3 trials, including TEBE-AM with enrollment completion anticipated and topline data expected as early as second half 2026, and ATOM described as the only active registrational Phase 3 in adjuvant uveal melanoma.
  • + Pipeline expansion with a Phase 1 type 1 diabetes CTA submitted (first patient dosing expected in 2026), promising hepatitis B Phase 1 results at AASLD, and an HIV functional cure program presented at CROI.
Bearish
  • − Expectation of moderating growth as KIMTRAK enters its fifth year on the market.
  • − Ovarian brenetafusp readout will be predominantly smaller safety cohorts and not a clear line of sight for monotherapy accelerated approval, and lung data is described as signal searching across heterogeneous subsets.
  • − TEBE-AM topline data timing is event-driven and dependent on overall survival events, with the company acknowledging it could slip beyond the current as-early-as 2H 2026 window.
  • − Pivoting of the ovarian program away from monotherapy accelerated approval reflects prior difficulty establishing a clear regulatory pathway in that setting.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 14.9 · calm Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +9%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 71%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +8%
trailing
6-month return +10%
trailing
YTD return +6%
this year
Relative strength −4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.33% of float · ▼ -3.9% MoM · 18.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
136 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
Revenue growth +43%
Y/Y
EPS growth +30%
Y/Y
Free cash flow $-15.1M
Quant / Vol
risk profile
Moderate
Volatility 38%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
71% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.33% of float · ▼ -3.9% MoM · 18.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
136 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $28 Now $37 · 71% Range high $40
vs 200-day avg +12% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $880.2M as of June 30, 2026 —
KIMMTRAK sales in Europe $131.4M FY 2025 —
KIMMTRAK sales in international regions $11.6M FY 2025 —
KIMMTRAK sales in the United States $257M FY 2025 —
Mean duration of treatment 14 FY 2025 —
Year-over-year sales growth in Europe 79% FY 2025 —
Year-over-year sales growth in the United States 13% FY 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMCR
Immunocore Holdings plc
this stock
$1.89B +5.5% +43.1% — 15.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $64.16B +22.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
136
% held
102.5%
Net QoQ
-1.4M sh
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
58
View
Short & Settlement
Short Interest Falling
Shares short
7.9M
Days to cover
18.8d
Change
-322.2K sh
View
Short Volume
Short vol %
36%
As of
Aug 31, 2026
Short Total
View
Fails to Deliver
FTD shares
37.0K
Value
$1.3M
As of
Aug 10, 2026
View
Off-Exchange
Off-exchange %
45.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$400.0M
Net income (FY)
$-35.5M
EPS diluted
$-0.71
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
11
View
Proposed Sales
Value
$385.3K
Shares
11.8K
Filed
Mar 11, 2026
View
Exempt Offerings
Offering
$140.0M
Filed
Jul 28, 2022
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
IMCR -0.7% +8.3% +9.6% +8.3% +5.5%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -1.2% +5.3% -3.8% +5.3% -7.3%
Key facts CIK 1671927 CUSIP 45258D105 13F (30d) 121 filings 115 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)